- Home
- SATX vs LCTX Comparison
SATX vs LCTX Comparison
Compare SATX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATX
- LCTX
- Stock Information
- Founded
- SATX 2012
- LCTX 1990
- Country
- SATX Israel
- LCTX United States
- Employees
- SATX N/A
- LCTX N/A
- Industry
- SATX Radio And Television Broadcasting And Communications Equipment
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SATX Technology
- LCTX Health Care
- Exchange
- SATX Nasdaq
- LCTX Nasdaq
- Market Cap
- SATX 130.6M
- LCTX 127.7M
- IPO Year
- SATX N/A
- LCTX N/A
- Fundamental
- Price
- SATX $1.39
- LCTX $0.68
- Analyst Decision
- SATX Strong Buy
- LCTX Strong Buy
- Analyst Count
- SATX 2
- LCTX 4
- Target Price
- SATX $2.25
- LCTX $4.50
- AVG Volume (30 Days)
- SATX 155.8K
- LCTX 1.2M
- Earning Date
- SATX 03-04-2025
- LCTX 03-06-2025
- Dividend Yield
- SATX N/A
- LCTX N/A
- EPS Growth
- SATX N/A
- LCTX N/A
- EPS
- SATX N/A
- LCTX N/A
- Revenue
- SATX $10,351,000.00
- LCTX $8,719,000.00
- Revenue This Year
- SATX $73.52
- LCTX N/A
- Revenue Next Year
- SATX $4.09
- LCTX $41.15
- P/E Ratio
- SATX N/A
- LCTX N/A
- Revenue Growth
- SATX N/A
- LCTX N/A
- 52 Week Low
- SATX $0.50
- LCTX $0.48
- 52 Week High
- SATX $2.39
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- SATX 54.03
- LCTX 53.39
- Support Level
- SATX $1.13
- LCTX $0.58
- Resistance Level
- SATX $1.55
- LCTX $0.73
- Average True Range (ATR)
- SATX 0.17
- LCTX 0.05
- MACD
- SATX 0.00
- LCTX 0.00
- Stochastic Oscillator
- SATX 56.92
- LCTX 50.67
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd develops end-to-end next-generation satellite communications systems, including satellite payloads, user terminals and modems, based on powerful chipsets that it develops in house. Its products include modems that feature Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the advanced communications standard DVB-S2X. Geographical presence in U.S, Canada, UK and Other countries. Majority of its company revenue comes from U.S and Canada.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.